Table 3 Multivariable analysis of prognostic factors for rate of laboratory measurement according to zero-inflated negative binomial models
Liver (AST/ALT) | Renal (Creatinine) | Metabolic (Lipids) | |||||||
|---|---|---|---|---|---|---|---|---|---|
(N = 3934) | (N = 3530) | (N = 3530) | |||||||
Rate ratio | 95 % CI | p-value | Rate ratio | 95 % CI | p-value | Rate ratio | 95 % CI | p-value | |
Negative binomial | |||||||||
Province | |||||||||
British Columbia | Ref | Ref | Ref | ||||||
Ontario | 0.98 | (0.94,1.03) | 0.48 | 1.35 | (1.29,1.42) | <0.0001 | 1.13 | (1.05,1.21) | <0.001 |
Quebec | 1.20 | (1.13,1.27) | <0.0001 | 1.70 | (1.60,1.80) | <0.0001 | 1.45 | (1.34,1.57) | <0.0001 |
Age (per 10 years) | 1.02 | (1.00,1.04) | 0.03 | 1.03 | (1.01,1.05) | <0.01 | 1.05 | (1.02,1.08) | 0.0001 |
Male | 1.02 | (0.98,1.07) | 0.37 | 1.01 | (0.96,1.06) | 0.72 | 1.14 | (1.07,1.22) | 0.0001 |
Race | |||||||||
Caucasian | Ref | Ref | Ref | ||||||
Black | 1.03 | (0.97,1.10) | 0.37 | 0.93 | (0.86,1.00) | 0.04 | 0.80 | (0.72,0.89) | <0.0001 |
Aboriginal | 0.87 | (0.79,0.96) | <0.01 | 0.87 | (0.79,0.97) | <0.01 | 0.84 | (0.72,0.97) | 0.02 |
Other | 1.11 | (1.04,1.18) | <0.01 | 1.09 | (1.02,1.16) | <0.01 | 1.06 | (0.97,1.16) | 0.19 |
Unknown | 0.89 | (0.85,0.93) | <0.0001 | 0.92 | (0.88,0.96) | <0.001 | 0.76 | (0.71,0.81) | <0.0001 |
HCV and IDU status | |||||||||
HCV-non-IDU | Ref | Ref | Ref | ||||||
HCV+ non-IDU | 1.05 | (0.97,1.14) | 0.21 | 1.07 | (0.99,1.15) | 0.09 | 1.00 | (0.89,1.12) | 0.99 |
HCV-IDU | 0.98 | (0.89,1.07) | 0.62 | 0.95 | (0.87,1.05) | 0.31 | 0.95 | (0.83,1.08) | 0.43 |
HCV+ IDU | 0.79 | (0.74,0.83) | <0.0001 | 0.80 | (0.75,0.85) | <0.0001 | 0.65 | (0.59,0.71) | <0.0001 |
Unknown | 0.97 | (0.93,1.02) | 0.21 | 1.00 | (0.96,1.04) | 0.96 | 1.28 | (1.20,1.36) | <0.0001 |
CD4 measurements: | |||||||||
<3 per year | Ref | Ref | Ref | ||||||
3-5 per year | 1.87 | (1.79,1.95) | <0.0001 | 1.76 | (1.68,1.84) | <0.0001 | 1.84 | (1.73,1.97) | <0.0001 |
≥6 per year | 2.67 | (2.52,2.83) | <0.0001 | 2.56 | (2.41,2.71) | <0.0001 | 2.79 | (2.56,3.03) | <0.0001 |
First cART regimen | |||||||||
Other | Ref | Ref | Ref | ||||||
NNRTI based | 0.95 | (0.86,1.05) | 0.32 | 0.97 | (0.88,1.06) | 0.47 | 0.78 | (0.68,0.90) | <0.001 |
Boosted PI based | 0.96 | (0.87,1.07) | 0.48 | 1.01 | (0.91,1.11) | 0.89 | 0.88 | (0.77,1.02) | 0.08 |
PI based | 0.95 | (0.85,1.05) | 0.32 | 0.95 | (0.86,1.05) | 0.35 | 0.78 | (0.67,0.90) | <0.001 |
Abacavir use | -- | -- | -- | -- | -- | 1.13 | (1.08,1.18) | <0.0001 | |
Tenofovir use | -- | -- | -- | 0.99 | (0.96,1.03) | 0.68 | -- | -- | -- |
Zero-inflated | |||||||||
IDU | 0.19 | (0.11,0.32) | <0.0001 | 0.22 | (0.15, 0.34) | <0.0001 | 0.17 | (0.11,0.26) | <0.0001 |
Unknown HIV risk factor | 1.32 | (0.50,3.48) | 0.58 | 1.14 | (0.59,2.19) | 0.70 | 0.96 | (0.43,2.14) | 0.92 |